A 12-Week, Prospective, Open-Label Analysis of the Effect of Rosuvastatin on Triglyceride-Rich Lipoprotein Metabolism in Patients with Primary Dyslipidemia

This publication has 46 references indexed in Scilit:

• Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study
  The Lancet, 2006
• Treating to target patients with primary hyperlipidaemia:comparison of the effects of ATOrvastatin and ROSuvastatin (the ATOROS study)
  Current Medical Research and Opinion, 2006
• The effects of statins on high-density lipoproteins
  Current Atherosclerosis Reports, 2006
• New Lipid-lowering Agents Acting on LDL Receptors
  Current Topics in Medicinal Chemistry, 2005
• The triglyceride–high-density lipoprotein axis: An important target of therapy?
  American Heart Journal, 2004
• Statins as the cornerstone of drug therapy for dyslipidemia: monotherapy and combination therapy options
  American Heart Journal, 2004
• Attaining United Kingdom-European Atherosclerosis Society Low-density Lipoprotein Cholesterol Guideline Target Values in the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study
  Current Medical Research and Opinion, 2002
• The Magnitude of Decrease in Hepatic Very Low Density Lipoprotein Apolipoprotein B Secretion Is Determined by the Extent of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibition in Miniature Pigs
  Endocrinology, 1999
• Metabolic modes of action of the statins in the hyperlipoproteinemias
  Atherosclerosis, 1998
• Simvastatin decreases the hepatic secretion of very‐low‐density lipoprotein apolipoprotein B‐100 in heterozygous familial hypercholesterolaemia: pathophysiological and therapeutic implications
  European Journal of Clinical Investigation, 1995